Literature DB >> 6975136

Effect of 2'-deoxycoformycin on erythroid, granulocytic, and T-lymphocyte colony growth.

M T Aye, J V Dunne.   

Abstract

The finding of elevated intracellular levels of adenosine deaminase (ADA) in some patients with acute lymphoblastic leukemia has led to attempts to control this disease with the adenosine deaminase inhibitor 2'-deoxycoformycin (dCF). Because of clinical reports indicating its relative freedom from myelotoxicity, we have tested the effects of this drug on erythroid, granulocytic, and T-lymphocyte colony formation by normal marrow and peripheral blood cells. While clinically the drug has been found to be active at serum concentrations of approximately 10 microM, we have tested it at concentrations up to and including 1 mM. It was found that both erythroid and granulocytic colony growth was completely unaffected by 1 mM dCF, a concentration at least 2 magnitudes higher than that necessary to totally ablate intracellular ADA levels. T-lymphocyte colony growth was unaffected by 100 microM dCF, but at 1 mM some inhibition was observed. These findings therefore indicate that dCF, while able to cause leukemic cell lysis in vivo, has no inhibitory effect on the proliferative capacity of normal hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975136

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.

Authors:  R F Kefford; R M Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

2.  Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.

Authors:  Simrit Parmar; Borje S Andersson; Daniel Couriel; Mark F Munsell; Marcelo Fernandez-Vina; Roy B Jones; Elizabeth J Shpall; Uday Popat; Paolo Anderlini; Sergio Giralt; Amin Alousi; Pedro Cano; Doyle Bosque; Chitra Hosing; Leandro de Padua Silva; Michael Westmoreland; J Kyle Wathen; Donald Berry; Richard E Champlin; Marcos J de Lima
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

3.  Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.

Authors:  Ming J Poi; Craig C Hofmeister; Jeffrey S Johnston; Ryan B Edwards; Buffy S Jansak; David M Lucas; Sherif S Farag; James T Dalton; Steven M Devine; Michael R Grever; Mitch A Phelps
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

4.  2'-Deoxycoformycin (Pentostatin) in hairy cell leukemia: response in patients refractory to interferon alpha.

Authors:  A D Ho; R Kuse; O Prümmer; F Porzsolt; W Hunstein
Journal:  Klin Wochenschr       Date:  1987-10-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.